K221326

Substantially Equivalent

Nova Allegro HbA1c Assay, Nova Allegro Analyzer

Applicant: Nova Biomedical Corporation
Product code: LCP
Advisory panel: Hematology
Date received: 2022-05-06
Decision date: 2024-11-22
Decision: Substantially Equivalent
Clearance type: Dual Track
Location: Walham, MA, US

Download summary PDF View on FDA.gov ↗

Data sourced from openFDA. This site is unofficial and independent of the FDA.